Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Pere Barba, MD, PhD
Advertisement
Articles by Pere Barba, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
5